- Title: Subtitle
- NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE
- Creators
- Jonathan R. Strosberg - Moffitt Cancer CenterEdward M. Wolin - University of KentuckyBeth Chasen - The University of Texas MD Anderson Cancer CenterMatthew H. Kulke - Dana-Farber Cancer InstituteDavid L Bushnell - United States Department of Veterans AffairsMartyn E. Caplin - The Royal Free HospitalRichard P. Baum - Zentralklinik Bad BerkaTimothy J. Hobday - Mayo ClinicAndrew Eugene Hendifar - Cedars-Sinai Medical CenterKjell E. Oberg - Uppsala University HospitalMaribel Lopera Sierra - Advanced Accelerator Applications, New York, NYDik J. Kwekkeboom - Erasmus MCPhilippe B. Ruszniewski - Beaujon HospitalEric Krenning - Erasmus MCPamela L. Kunz - Stanford University
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.34(15_suppl), pp.4005-4005
- DOI
- 10.1200/JCO.2016.34.15_suppl.4005
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 05/20/2016
- Academic Unit
- Radiology
- Record Identifier
- 9984320090202771
Abstract
NETTER-1 phase III: Efficacy and safety results in patients with midgut neuroendocrine tumors treated with 177 Lu-DOTATATE
Journal of clinical oncology, Vol.34(15_suppl), pp.4005-4005
05/20/2016
DOI: 10.1200/JCO.2016.34.15_suppl.4005
Details
Metrics
12 Record Views